Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRL201104 in Seasonal Allergic Rhinitis
NCT05098522Phase 2Completed
- Sponsor
- Revolo Biotherapeutics
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IRL201104 in seasonal allergic rhinitis (SAR), sponsored by Revolo Biotherapeutics. Started Nov 2021; status: completed.
02
Drugs
IRL201104
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT05098522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098522.